Pharmacologically, compared to age-matched health controls, PD is associated with a decrease in adenosine A2A receptors in the dorsal striatum, an increase in the substantia nigra pars reticulata, but with no change in any other brain regions (Hurley et al. 2000). The gene discussed is ADORA2A; the disease is Parkinson disease.